International Research Projects

Immunometabolomics CD8+ T cell metabolism in anti-tumor response.

Call
H2020-MSCA-IF-2016.
Principal investigator
Dr. Agustin Lahoz, Dr. Juan Carlos García Cañaveras
Role
Individual
Year
2017

The main objective of the Immunometabolomics project is to understand metabolism in CD8+ T cells, during active effector T cell development and exhaustion, using approaches that go beyond current research which have been mostly focused on glucose/energy metabolism thus disregarding the relevance of anabolic and redox reactions that are crucial in correct cellular function and proliferation.

CrowdHEALTH Collective wisdom driving public health policies.

Call
H2020-SC1-2016-CNECT.
Principal investigator
Dr. Bernardo Valdivieso
Role
Participant
Year
2017

CrowdHEALTH will introduce a new paradigm of Holistic Health Records (HHRs) that include all health determinants. HHRs will be transformed into Social HHRs communities capturing the clinical, social and human context of the population segmentation and as a result the collective knowledge for different factors depending on the communities formulation criteria (e.g. demographics, diseases, lifestyle choices, nutrition, etc).

HARMONY Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY.

Call
H2020-JTI-2015-06-two-stage.
Principal investigator
Dr. Guillermo Sanz
Role
Co-Chair
Year
2016

HARMONY is a European Network of Excellence that captures, integrates, analyzes and harmonizes Big Data from high-quality multidisciplinary sources for the purpose of acquiring valuable knowledge across the spectrum of hematologic malignancies (HMs). HARMONY will focus on HM disease areas with a high unmet need: multiple myeloma (MM), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphomas (NHL), myelodysplastic syndromes (MDS), and pediatric HMs.

Cardio-respiratory responses in dolphins Cardiorespiratory physiology in the bottlenose dolphin before, during, and after breath-holding and restraint.

Call
Office of Naval Research Contracts&Grants 2015.
Principal investigator
Dr. Andreas Fahlman
Role
Individual
Year
2016

The proposed work is intended to evaluate cardiorespiratory (heart rate, stroke volume, systemic and pulmoarterial pressures, respiratory flow and expired gas composition) function in a small cetacean, the bottlenose dolphin, at rest, during apnea, during recovery from apnea and during and following a stressful situation. In addition, we will use these data to extract medical biomarkers from animals that are adapted to a range of extreme physiological challenges (e.g. hypoxia, ischemia/reperfusion, atelectasis). These biomarkers may provide valuable information for human clinical medicine.

Hibbs Association between Intermittent Hypoxia and Later Respiratory Morbidity.

Call
NIH-R01-HL16-015
Principal investigator
Dr. Máximo Vento
Role
Consultant
Year
2016

Longer term respiratory morbidity remains a major consequence of preterm birth. The hypotheses will be in Aims 1 and 2 that IH episodes at one week and one month of life are significantly associated with prolonged duration of hospitalization and respiratory support, as well as a high incidence of wheezing disorders by six months adjusted age. In Aim 3 that low serotonin levels are associated with a high incidence of IH and a prolonged recovery of respiratory effort after onset of desaturation. Finally, in Aim 4 a temporal relationship between IH episodes and markers of oxidative stress determined by urine and blood samples.

ALBINO Effect of allopurinol in addition to hypothermia for hypoxic-ischemic brain injury on neurocognitive outcome.

Call
H2020-PHC-18-2015-two-stage.
Principal investigator
Dr. Máximo Vento
Role
Participant
Year
2015

This project aims to evaluate the efficacy and safety of allopurinol administered immediately after birth to near-term infants with HIE in addition to hypothermic treatment. The project will also provide information on the effect of hypothermia on pharmacokinetics of drugs with a similar metabolism as allopurinol in neonates, and develop and validate biomarkers for neonatal brain injury using advanced magnetic resonance imaging, biochemistry, and electroencephalogramms, which will then be available for future studies testing neuroprotective interventions.

COBIOPHAD Compact biophotonic platform for drug allergy diagnosis.

Call
H2020-ICT-28-2015.
Principal investigator
Dr. Dolores Hernández F. de Rojas
Role
Participant
Year
2015

COBIOPHAD aims the development of an innovative in vitro diagnostic (IVD) device for diagnosis of IgE-mediated drug allergies by building an integrated biophotonic system based on compact disc technology. For that, key enabling technologies will be integrated in order to achieve high sensitive (<0.1 kUA/L), selective (>98%), multiplexed (10 BLCs), rapid (30 min), and low-cost (2.4 €/allergen) drug allergy test. The solution involves an advanced approach to the diagnosis and management of drug allergy with the aim to ameliorate patient safety.

TORPIDO-2 Targeted Oxygenation in the Resuscitation of Premature Infants: Effects on Developmental Outcome – the TORPIDO2 Study.

Call
National Health and Medical Research Council (NHMRC), 2015.
Principal investigator
Dr. Máximo Vento
Role
Participant
Year
2015

The TORPIDO 2 study is a pragmatic, randomised controlled trial (RCT) in infants between 23 weeks and 28 weeks 6 days gestation which aims to test one primary and two secondary hypotheses; that, compared with starting resuscitation with 60% oxygen and a targeted oxygen saturation (SpO2) strategy, starting resuscitation with room air (21% oxygen) and the same targeted SpO2 strategy will improve the survival without major disability at 2 years corrected for gestation.

WiBEC Wireless in-body environment communications.

Call
H2020-MSCA-ITN-2015-ETN.
Principal investigator
Dr. Vicente Pons
Role
Participant
Year
2015

The main objective is to provide high quality and innovative doctoral training to develop the wireless technologies for novel implantable devices that will contribute to the improvement in quality and efficacy of healthcare.

More info

EUToxRisk21 EUTOXRISK21. An Integrated EUropean ‘Flagship’ Program Driving Mechanism-based Toxicity Testing and Risk Assessment for the 21st Century.

Call
H2020-PHC-33-2015-single-stage_RTD.
Principal investigator
Dr. José Vicente Castell Ripoll
Role
Participant
Year
2015

The project will focus on repeated dose systemic toxicity (liver, kidney, lung and nervous system) as well as developmental/reproduction toxicity. EUToxRisk21 extensively integrates the adverse outcome pathway (AOP)-based toxicity testing concept, with advanced technologies, including high throughput transcriptomics, RNA interference, and high throughput microscopy, providing quantitative and mechanistic underpinning of AOPs and key events (KE). The project combines in silico tools and in vitro assays by computational modelling approaches to provide quantitative data on the activation of KE of AOP. This information, together with detailed toxicokinetics data, and in vitro-in vivo extrapolation algorithms forms the basis for improved hazard and risk assessment.

More info